Cargando…

Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil

The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Rachel A., Faulkner, Michele A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619699/
https://www.ncbi.nlm.nih.gov/pubmed/23650473
http://dx.doi.org/10.4137/JCNSD.S9107
_version_ 1782265504614842368
author Burke, Rachel A.
Faulkner, Michele A.
author_facet Burke, Rachel A.
Faulkner, Michele A.
author_sort Burke, Rachel A.
collection PubMed
description The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-patient variability in bioavailability is lower than that of gabapentin. Studies have demonstrated superiority of gabapentin enacarbil compared to placebo. Comparisons to currently available RLS treatments are lacking, but clinical trials demonstrate comparable improvement in RLS symptoms to the dopamine agonists ropinirole and pramipexole, which are usually considered first-line therapy for daily RLS symptoms. Gabapentin enacarbil was well tolerated in clinical trials. The role of the drug in RLS treatment remains undefined, although it will likely be used as an alternative for refractory RLS when other treatments have failed. Additionally, gabapentin enacarbil may be recommended for patients with daily RLS symptoms that are less intense or are associated with pain as an alternative to dopamine agonists.
format Online
Article
Text
id pubmed-3619699
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36196992013-05-06 Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil Burke, Rachel A. Faulkner, Michele A. J Cent Nerv Syst Dis Review The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-patient variability in bioavailability is lower than that of gabapentin. Studies have demonstrated superiority of gabapentin enacarbil compared to placebo. Comparisons to currently available RLS treatments are lacking, but clinical trials demonstrate comparable improvement in RLS symptoms to the dopamine agonists ropinirole and pramipexole, which are usually considered first-line therapy for daily RLS symptoms. Gabapentin enacarbil was well tolerated in clinical trials. The role of the drug in RLS treatment remains undefined, although it will likely be used as an alternative for refractory RLS when other treatments have failed. Additionally, gabapentin enacarbil may be recommended for patients with daily RLS symptoms that are less intense or are associated with pain as an alternative to dopamine agonists. Libertas Academica 2012-09-17 /pmc/articles/PMC3619699/ /pubmed/23650473 http://dx.doi.org/10.4137/JCNSD.S9107 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Burke, Rachel A.
Faulkner, Michele A.
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title_full Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title_fullStr Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title_full_unstemmed Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title_short Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
title_sort review of the treatment of restless legs syndrome: focus on gabapentin enacarbil
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619699/
https://www.ncbi.nlm.nih.gov/pubmed/23650473
http://dx.doi.org/10.4137/JCNSD.S9107
work_keys_str_mv AT burkerachela reviewofthetreatmentofrestlesslegssyndromefocusongabapentinenacarbil
AT faulknermichelea reviewofthetreatmentofrestlesslegssyndromefocusongabapentinenacarbil